Kwon Hee, Director of Life Semantics, Receives Ministerial Commendation for Venture Startup Promotion Contributions

Contribution to Pioneering the DTx Market and Advancing the Industry

Kwon Hee, Director of DH·DTx Division at LifeSemantics

[Asia Economy Reporter Chunhee Lee] Digital health company LifeSemantics announced on the 16th that it received the Minister of SMEs and Startups Commendation at the 2022 Venture Startup Promotion Merit Awards. Now in its 25th year, the Venture Startup Promotion Merit Awards is an event hosted by the Ministry of SMEs and Startups to discover and encourage outstanding venture and startup companies.

Kwon Hee, director of LifeSemantics, who won in the venture activation category, was recognized for pioneering the market and contributing to the development of related industries through the development and empirical research of the country's first digital therapeutic device (DTx) for respiratory disease patients. Director Kwon, belonging to LifeSemantics DH/DTx Lab, has made great efforts to build the domestic DTx ecosystem, develop core technologies, and advance technology. He has filed two patents, including "Method for Providing Digital Therapy for Rehabilitation of Respiratory Disease Patients" and "System and Method for Semantic Interoperability Processing of Heterogeneous Health Measurement Device Data Exchange," and serves as a clinical trial executor for exploration and confirmation in the domestic DTx field, guiding technology and administrative consulting for later companies. In addition, he has actively participated in various government-led national projects related to digital healthcare for 10 years, leading public-private cooperation.

Director Kwon said, "I am very pleased to receive this valuable award for the activation of the DTx market and venture companies," adding, "It is a particularly meaningful award as I received it while being part of the process of the birth of a new field called DTx from the early days of the domestic digital healthcare market." He continued, "DTx eliminates patients' spatial and temporal constraints and has fewer side effects compared to pharmaceuticals, attracting global market interest, but since it applies new concepts and technologies, there are many challenges to overcome. We will do our best in technology development and commercialization so that more people can safely use DTx and become healthier without disrupting the existing medical market order."

LifeSemantics logo (Photo by LifeSemantics)

This content was produced with the assistance of AI translation services.